Epidemiology and Risk Factors for Echinocandin NonsusceptibleCandida glabrataBloodstream Infections: Data From a Large Multisite Population-Based Candidemia Surveillance Program, 2008–2014

Declining Incidence of Candidemia and the Shifting Epidemiology of Candida Resistance in Two US Metropolitan Areas, 2008–2013: Results from Population-Based Surveillance

(2015) Angela Ahlquist Cleveland et al.   PLoS One

FKS Mutant Candida glabrata: Risk Factors and Outcomes in Patients With Candidemia

(2014) N. D. Beyda et al.   CLINICAL INFECTIOUS DISEASES

Emergence of echinocandin-resistant Candida spp. in a hospital setting: a consequence of 10 years of increasing use of antifungal therapy?

(2014) A. Fekkar et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Evaluation of antifungal use in a tertiary care institution: antifungal stewardship urgently needed

(2014) M. Valerio et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Multistate Point-Prevalence Survey of Health Care–Associated Infections

(2014) Shelley S. Magill et al.   NEW ENGLAND JOURNAL OF MEDICINE

Epidemiology and Outcomes of Invasive Candidiasis Due to Non-albicans Species of Candida in 2,496 Patients: Data from the Prospective Antifungal Therapy (PATH) Registry 2004–2008

(2014) Michael A. Pfaller et al.   PLoS One

Increasing Echinocandin Resistance in Candida glabrata: Clinical Failure Correlates With Presence of FKS Mutations and Elevated Minimum Inhibitory Concentrations

(2013) Barbara D. Alexander et al.   CLINICAL INFECTIOUS DISEASES

Development of a Luminex-Based Multiplex Assay for Detection of Mutations Conferring Resistance to Echinocandins in Candida glabrata

(2013) C. D. Pham et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Toxicity Mechanisms of Amphotericin B and Its Neutralization by Conjugation with Arabinogalactan

(2012) Sarah Kagan et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The Presence of anFKSMutation Rather than MIC Is an Independent Risk Factor for Failure of Echinocandin Therapy among Patients with Invasive Candidiasis Due to Candida glabrata

(2012) Ryan K. Shields et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Changes in Incidence and Antifungal Drug Resistance in Candidemia: Results From Population-Based Laboratory Surveillance in Atlanta and Baltimore, 2008-2011

(2012) A. A. Cleveland et al.   CLINICAL INFECTIOUS DISEASES

Frequency of Decreased Susceptibility and Resistance to Echinocandins among Fluconazole-Resistant Bloodstream Isolates of Candida glabrata

(2012) M. A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Species Identification and Antifungal Susceptibility Testing of Candida Bloodstream Isolates from Population-Based Surveillance Studies in Two U.S. Cities from 2008 to 2011

(2012) S. R. Lockhart et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Prior Caspofungin Exposure in Patients with Hematological Malignancies Is a Risk Factor for Subsequent Fungemia Due to Decreased Susceptibility in Candida spp.: a Case-Control Study in Paris, France

(2011) Elodie Blanchard et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

FKS Mutations and Elevated Echinocandin MIC Values among Candida glabrata Isolates from U.S. Population-Based Surveillance

(2010) A. J. Zimbeck et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Is age a risk factor for Candida glabrata colonisation?

(2010) Anurag N. Malani et al.   MYCOSES

Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America

(2009) Peter G. Pappas et al.   CLINICAL INFECTIOUS DISEASES

Variation in Susceptibility of Bloodstream Isolates of Candida glabrata to Fluconazole According to Patient Age and Geographic Location in the United States in 2001 to 2007

(2009) M. A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Resistance to Antifungal Agents: Mechanisms and Clinical Impact

(2007) Z. A. Kanafani et al.   CLINICAL INFECTIOUS DISEASES